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ABSTRACT
Objectives Osteoarthritis (OA) is the most common
form of arthritis with a clear genetic component. To
identify novel loci associated with hip OA we performed
a meta-analysis of genome-wide association studies
(GWAS) on European subjects.
Methods We performed a two-stage meta-analysis on
more than 78 000 participants. In stage 1, we
synthesised data from eight GWAS whereas data from
10 centres were used for ‘in silico’ or ‘de novo’
replication. Besides the main analysis, a stratiﬁed by sex
analysis was performed to detect possible sex-speciﬁc
signals. Meta-analysis was performed using inverse-
variance ﬁxed effects models. A random effects approach
was also used.
Results We accumulated 11 277 cases of radiographic
and symptomatic hip OA. We prioritised eight single
nucleotide polymorphism (SNPs) for follow-up in the
discovery stage (4349 OA cases); ﬁve from the combined
analysis, two male speciﬁc and one female speciﬁc. One
locus, at 20q13, represented by rs6094710 (minor allele
frequency (MAF) 4%) near the NCOA3 (nuclear receptor
coactivator 3) gene, reached genome-wide signiﬁcance
level with p=7.9×10−9 and OR=1.28 (95% CI 1.18 to
1.39) in the combined analysis of discovery
(p=5.6×10−8) and follow-up studies (p=7.3×10−4).
We showed that this gene is expressed in articular
cartilage and its expression was signiﬁcantly reduced in
OA-affected cartilage. Moreover, two loci remained
suggestive associated; rs5009270 at 7q31 (MAF 30%,
p=9.9×10−7, OR=1.10) and rs3757837 at 7p13 (MAF
6%, p=2.2×10−6, OR=1.27 in male speciﬁc analysis).
Conclusions Novel genetic loci for hip OA were found
in this meta-analysis of GWAS.
INTRODUCTION
Osteoarthritis (OA) is the most common form of
arthritis affecting 40% of people over the age of
70 years and is one of the most common disabling
diseases observed worldwide.1 2 Its aetiology is
multifactorial with a clear genetic component.
Inheritance studies in twins and other family-based
studies have assessed the estimated heritability for
OA in the range of 40–65% depending on the joint
site.3–5 The established OA loci have small ORs
(range 1.10–1.20)6 7 and the genetic architecture of
OA is likely to consist of multiple variants of
similar magnitude.
During the last few years, extensive efforts have
led to the identiﬁcation of a number of OA suscep-
tibility signals in European populations that have
surpassed the genome-wide signiﬁcance (GWS)
level (p<5×10−8). A locus on chr7q22 near the
orphan receptor GPR22 derived from genome-wide
association studies (GWAS)8 9 and a variant in the
GDF5 gene, originating from a candidate gene
approach reached GWS for knee OA.10 An analysis
using a 1000-genomes-project-based imputations
identiﬁed a variant on chromosome 13q34 near the
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MCF2L gene.7 A recent GWAS in UK subjects revealed eight
more loci that increase risk for OA. From those eight loci, four
signals in 9q33 (ASTN2), 6q14 (FILIP1/SENP6), 12p11
(KLHDC5/PTHLH) and 12q23 (CHST11) were found to be
associated with total hip replacement (THR) or hip OA in
European populations.6 Finally, GWAS and functional studies
revealed that the DOT1L gene on 19q13 is also associated with
hip OA and cartilage thickness.11 12
In this study a large-scale GWAS meta-analysis for hip OA was
performed under the auspices of the Translational Research in
Europe Applied Technologies in Osteoarthritis (TreatOA) con-
sortium including eight sample sets, in the discovery stage. With
a total of 4349 hip OA cases and 46 903 controls in the discov-
ery stage, and a total of 11 277 cases and 67 473 controls, this
is the largest study of hip OA to date.
METHODS
Study design and analysis plan
A two-stage design was used for the identiﬁcation of potential
associations. In the discovery stage imputed and directly geno-
typed autosomal single nucleotide polymorphism (SNPs) were
assessed using a quality control (QC) procedure that is described
in the online supplementary material (section 1.a). Brieﬂy, we
excluded SNPs based on low minor allele frequency (MAF
<1%), low imputation quality, low call rate and deviation from
the Hardy-Weinberg equilibrium. Genomic control was applied
to each study before meta-analysis. The effect estimates of each
study where synthesised using an additive model. The variants
that surpassed the p<1×10−6 threshold in the meta-analysis
were selected for further follow-up. Besides the main analysis
including all participants a separate analysis stratiﬁed by sex was
performed to detect possible sex-speciﬁc signals. In silico and de
novo replication was sought for the discovery signals in 10 add-
itional studies. All the derived effects from the discovery and
the replication stage were ﬁnally synthesised using inverse vari-
ance ﬁxed-effect models and the between-study heterogeneity
was assessed using the I2metric.13 Moreover, a random-effects
(RE) model was applied.14 A p-value of <5×10−8 was consid-
ered GWS. The associations of the top ﬁndings at the discovery
stage were also assessed when adjusted for other risk factors
such as age, height and body mass index (BMI). We also exam-
ined the association of these markers with height and BMI in
the large publicly available sample set of the Genetic
Investigation of Anthropometric Traits (GIANT) consortium
(133 000 individuals in height analysis and 123 000 individuals
in BMI analysis.15 16 The detailed analysis plan is presented in
the online supplementary material (section 1.b).
Study populations and phenotype deﬁnition
The studies included in the discovery and replication efforts are
described in table 1 and more details are given in the online
supplementary material (section 1.c). All studies had standar-
dised deﬁnitions of the phenotypes. Speciﬁcally, the deﬁnition
of the hip OA in the studies was either a radiographic Kellgren
and Lawrence (K/L) grade of ≥2 or history of a THR surgery
because of OA. THR subjects were excluded from the study if
they had: other major arthropathy (eg, rheumatoid arthritis,
ankylosing spondylitis); Paget’s disease affecting the pelvis or
femur; THR due to hip trauma or avascular necrosis of the
femoral head; or terminal illness. The control groups consisted
of subjects who had no known affected joints. Population-based
controls were used by the arcOGEN study.
Table 1 Studies included in the TreatOA GWAS meta-analysis
Study
N
cases
N
controls λ N SNPs ROA/SOA Controls Genotyping platform
Imputation
method
Discovery stage
arcOGEN stage 1 1728 4896 1.058 2.454.242 ROA/SOA Population Illumina Human610 (cases)+Illumina 1.2M Duo (controls) Impute
deCODE 1423 31 385 1.182 2.399.690 SOA Osteoarthritis-free Infinium HumanHap 300+humanCNV370 Impute
EGCUT 64 2531 0.994 2.242.156 ROA Population Illumina HumanCNV370 or HumanOmniExpress Impute
GARP 106 1671 1.294 2.406.007 SOA/ROA KL<2 Illumina Infinium HD Human660W-Quad Impute
RSI 760 3233 1.009 2.450.385 ROA KL<2 Illumina HumanHap550v3 MACH
RSII 159 1472 0.993 2.442.419 ROA KL<2 Illumina HumanHap550-Duo MACH
RSIII 41 1487 0.962 2.397.764 ROA KL<2 Illumina Human660W-Quad MACH
TwinsUK 68 228 0.993 2.358151 ROA KL<2 Infinium HumanHap300 Impute
Total discovery 4349 46 903 1.028 2.567.279 – –
Replication stage
arcOGEN stage 2 1763 6157 1.058 – ROA/SOA – Illumina Human610 (cases)+Illumina 1.2M Duo (controls) Impute
SOF* 761 2376 1.008 – ROA – Illumina Omni 1 array (1.1 million probes) MACH
MrOS* 446 2837 1.002 – ROA – Illumina Omni 1 array (1.1 million probes) MACH
arcOGEN plus 223 1828 – – ROA/SOA – Illumina Human610 (cases)+Illumina 1.2M Duo (controls) Impute
EGCUT 977 1131 – – ROA – Illumina HumanCNV370 or HumanOmniExpress Impute
Greek TJR cases 93 361 – – SOA – Single base extension using SNaPshot Multiplex Kit (Applied
Biosystems, Foster City, USA))
–
Paprika Study 602 2321 – – SOA – Sequenom (MassARRAY iPLEX Gold) –
Spanish TJR cases 697 783 – – SOA – Single base extension using SNaPshot Multiplex Kit (Applied
Biosystems, Foster City, USA))
–
Icelandic cases 857 1857 – – SOA – Centaurus (Nanogen)37
Swedish MDC study 509 919 – – SOA – Centaurus (Nanogen)37 –
Total replication 6928 20 570 – –
Total 11 277 67 473 – –
EGCUT, Estonian Genome Center, University of Tartu; GWAS, genome-wide association studies; HD, high density; KL, Kellgren-Lawrence score; MDC, Malmo Diet Cancer study; MrOS,
Osteroporotic Fractures in Men study; ROA, radiographic osteoarthritis; SOA, symptomatic osteoarthritis; SOF, Study of Osteoporotic Fractures; TJR, total joint replacement.
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Genotyping and imputation
Genotyping of GWAS genotyping was performed by each study
following standard protocols and imputation was then carried out
at the individual study level on the ∼2.5 million SNPs from
HapMap Phase 2 release 22 using genome build 36 (Utah resi-
dents with ancestry from northern and western Europe (CEPH))17
on MACH or IMPUTE18 software. Imputation quality scores for
each SNP were obtained from IMPUTE and MACH statistics, as
appropriate. An overview of all studies and the genotyping plat-
forms and imputation method used is given in table 1. Ten studies
of European ancestral origin provided data for independent repli-
cation. Four datasets (arcOGEN stage 2, arcOGEN plus,
Osteroporotic Fractures in Men study and the Study of
Osteoporotic Fractures) provided ‘in silico’ replication whereas ‘de
novo’ replication was performed in six other study groups
(Icelandic, Swedish, Estonian Genome Center, University of Tartu
(EGCUT), Paprika study, Greek, Spanish). QC criteria for devi-
ation from Hardy-Weinberg equilibrium, MAF inconsistencies
with the discovery data and outliers were applied in the replication
data before including all the available data in the ﬁnal analysis.
Gene expression
Expression was determined by Illumina HT-12 V3 microarrays
using standard methods using 47 000 probes corresponding to
over 25 000 well-characterised genes. DNA was available from
blood and cartilage. Using the Beadstudio software the intensity
values were normalised using the ‘rsn’ option in the Lumi
R-package. The corresponding signals increase exponentially
with relative levels and units are light intensity (Illumina pro-
vided values). The obtained raw probe-level data (overall mean
normalised probe level value of measured genes in cartilage)
were exported for analyses using Limma.19 As implemented in
Limma, a paired t test was used on all samples. There were two
probes, approximately 2.2 kb apart, on the array used for
NCOA3.
Heritability of hip OA explained by genetic variants
We calculated the sibling recurrence risk and the expected
genetic variance explained for hip OA hits that were identiﬁed
previously and in this study as described in online supplementary
material (section 1.e)
RESULTS
The ﬁnal analysis included a total of 11 277 radiographic and
symptomatic hip OA cases and 67 473 controls of European
ancestry, with 4349 cases and 46 903 controls included in the
discovery stage and 6928 cases and 20 570 controls in the
follow-up effort (table 1). In the sex-speciﬁc analyses 2045/
20 823 male cases and controls and 2689/25 384 female cases
and controls were analysed in the discovery. After QC,
2 567 279 SNPs were analysed. Low genomic inﬂation factor
was observed for the ﬁrst stage with λ=1.028. The results of the
discovery stage were uncorrected for the overall inﬂation factor.
Quantile-Quantile plots showed an excess of signals compared
with what was expected by chance, indicating the presence of
true association signals that could confer susceptibility to hip
OA (see online supplementary ﬁgures S1–S3). For male-speciﬁc
analysis (see online supplementary ﬁgure S3) there is an early
deviation from the neutrality line, therefore positive signals
should be treated with caution.
Following analysis of the discovery stage it was found that
eight independent loci reached the prespeciﬁed threshold of
p<1.0×10−6 required for further replication; ﬁve from the
combined analysis of sexes, two male-speciﬁc and one female-
speciﬁc loci. The number of independent SNPs is larger com-
pared with three estimated independent SNPs expected under
the null for the main and the sex-speciﬁc analyses (binomial test
p=0.012). Two of these signals (rs6094710 at 20q13 and
rs640070 at 11q25) were imputed, had MAF <5% and moder-
ate or large effect sizes were observed (OR >1.2). Therefore,
we examined for possible imputation errors by comparing with
de novo genotyping in a random sample of the RS-I and the
Twins UK studies to exclude any chance of false positive ﬁnd-
ings. The obtained MAF estimates between the imputation and
the genotyping efforts were not consistent for rs640070,
which was therefore excluded from further consideration, mini-
mising the chance of any false positive signals (see online
supplementary material; section 1.d). Moreover, we included in
the replication stage rs17610181 at 17q23, a SNP that was just
below the desired threshold, but was previously shown to be
associated with height.15 Therefore, eight independent SNPs
were included in the replication phase. The combined effect
sizes and p values for the eight signals are presented in table 2
Table 2 Association results for hip OA meta-analysis of the discovery and the replication studies
SNP Chr Gene A1 EAF (%)
Discovery stage Replication stage Combined
OR (95% CI) p Value I2 (%) OR (95% CI) p Value OR (95% CI) p Value I2 (%)
H&E RE
p value
Combined analysis of both genders:
rs6094710 20q13 NCOA3 A 4 1.40 (1.24 to 1.58) 5.6×10−8 0 1.20 (1.08 to 1.34) 7.3×10−4 1.28 (1.18 to 1.39) 7.9×10−9 64 2.0×10−10
rs1577792 6q14 HMGN3 A 39 1.14 (1.09 to 1.20) 7.3×10−8 0 1.03 (0.99 to 1.07) 0.17 1.07 (1.04 to 1.11) 7.8×10−5 50 9.6×10−6
rs5009270 7q31 IFRD1 A 30 1.15 (1.09 to 1.21) 5.7×10−7 21 1.05 (1.00 to 1.11) 0.061 1.10 (1.06 to 1.14) 9.0×10−7 46 3.1×10−6
rs10773046 12q24 DNAH10 G 45 1.13 (1.08 to 1.19) 9.7×10−7 10 1.01 (0.96 to 1.06) 0.72 1.07 (1.03 to 1.11) 2.0×10−4 64 1.9×10−6
rs17610181 17q23 NACA2 A 14 1.20 (1.11 to 1.29) 1.9×10−6 32 1.05 (0.99 to 1.12 0.12 1.12 (1.06 to 1.18) 1.3×10−5 42 7.5×10−6
Female-specific analysis:
rs10878630 12q15 DYRK2 A 41 1.19 (1.11 to 1.26) 1.2×10−7 25 0.98 (0.91 to 1.05) 0.52 1.09 (1.04 to 1.14) 3.9×10−4 65 1.1×10−5
Male-specific analysis:
rs12551314 9q22 PHF2 A 12 1.30 (1.18 to 1.44) 6.3×10−7 28 0.98 (0.86 to 1.11) 0.72 1.16 (1.07 to 1.25) 2.9×10−4 66 4.3×10−5
rs3757837 7p13 CAMK2B C 6 1.46 (1.26 to 1.69) 8.3×10−7 46 1.15 (1.00 to 1.32) 0.044 1.27 (1.15 to 1.41) 2.2×10−6 78 7.7×10−10
The discovery sample set comprised 4349 hip OA cases and 46 903 controls, and the replication samples were 6928 cases and 20 570 controls in the analysis of both genders. The
female-specific analysis comprised 2689 hip OA cases and 25 384 controls in the discovery set and 2398 cases and 8787 controls in the replication stage. For the male-specific analysis
there were 2045 hip OA cases and 20 823 controls in the discovery set and 1386/7087 and 1451/4956 cases/controls in the replication stage for rs12551314 and rs3757837
respectively.
A1, coded/effect allele; Chr, chromosome; EAF, effect allele frequency; Gene, nearest gene; HE RE P, Han & Eskin Random Effects P; I2, measure of heterogeneity; OA, osteoarthritis.
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and in online supplementary ﬁgures S4–S11. None of these var-
iants associate with height or BMI in the large publicly available
GIANT databases (see online supplementary table S2) nor did
including these covariates, or age, in the analysis change the
association of OA with these genetic variants (see online
supplementary table S3).
Two SNPs, rs6094710 at 20q13 and rs1577792 at 6q14,
were borderline GWS in the discovery stage with p=5.8×10−8
and 7.3×10−8, respectively, with no observed heterogeneity
(I2=0). The SNP rs6094710 replicated with p=7.3×10−4 in the
follow-up samples and reached GWS level with p=9.3×10−9
and OR=1.28 (95% CI 1.17 to 1.39) when we combined the
discovery and the replication data, although large heterogeneity
was observed I2=64% (ﬁgure 1). The SNP remained GWS after
the second genomic control. rs6094710 is annotated near
NCOA3 (nuclear receptor coactivator 3) gene. The OR of
rs1577792 at 6q14 was close to unity in the replication effort
with one study being signiﬁcant in the opposite direction.
The rs3757837 SNP at 7p13 from the male-speciﬁc analysis
replicated nominally (p=0.044, OR=1.15) in the follow-up
samples, but did not reach GWS in the overall analysis with
p=2.2×10−6 and OR=1.27. Moderate heterogeneity was
observed for this SNP in the discovery analysis (I2=46%).
Heterogeneity was increased, in the overall analysis with all the
studies combined (I2=78%), reﬂecting the further heterogeneity
introduced by the replication data. We, therefore, also applied
the Han and Eskin (RE) model, an approach that allows more
heterogeneity in the data compared with traditional models.14
Using this model rs3757837 showed a stronger association with
p=7.7×10−10 in this analysis. The strength of the association of
this approach was not substantially different from the ﬁxed-effect
model for any other SNP in our study (table 2). rs3757837
resides in intron 8 of the CAMK2B (calcium/calmodulin-
dependent protein kinase II β) gene.
The rs5009270 SNP at 7q31 remained suggestively associated
in the ﬁnal analysis (p<5×10−6) with combined two-stage
p=9.9×10−7 and summary OR 1.10. rs5009270 is located near
the IFRD1 (interferon-related) gene. The p with the RE approach
was 3.1×10−6.
Gene expression data
To further investigate our ﬁndings for the top GWS hit at
20q13 we explored mRNA expression proﬁle of the NCOA3
gene in articular cartilage, a highly relevant tissue for OA.
Expression of the gene was examined by exploring a micro
array mRNA expression dataset generated on Illumina V3
Human-12 chips in cartilage samples of 33 patients (13 men
and 20 women of European descent aged 54 years to 80 years)
that underwent joint replacement due to end-stage OA disease.
Expression levels of NCOA3 in cartilage displaying symptoms of
OA were compared with expression levels in cartilage that
appeared macroscopically normal but isolated from the same
joint (preserved cartilage). A moderate level of expression, as
determined by the mean normalised probe level value, was
observed for NCOA3 (mean level 8.49), which was above the
observed average expression of genes in the articular cartilage
(mean normalised probe level value of measured genes in cartil-
age was 7.4; range 6.6–14.9). Expression was also high in blood
(6.96; range 6.3–14.7). When we tested for differential expres-
sion of NCOA3 among the pairs of preserved and OA-affected
cartilage, we observed a signiﬁcantly lower expression of
NCOA3 in the OA-affected cartilage (p=0.0064).
Heritability of hip OA explained by genetic variants
Table 3 summarises genome-wide signiﬁcant and suggestive
signals of hip OA including this study. Based on these ﬁndings
and if we consider a sibling recurrence ratio λs=5
20 then the dis-
covered signals of OA contribute 3% of the heritability in OA
Figure 1 (A) Forest plot for meta-analysis of rs6094710. The blue diamond in the forest plot denotes the summary effect size and its edges the
respective 95% CIs. Studies shaded in blue were included in the replication stage. *Discovery and replication estimate combined; and (B) regional
plot for rs6094710 comprising directly genotyped and imputed SNPs. Case-control association results (−log10 P) in the discovery set are plotted
against genomic position (National Center for Biotechnology Information build 36) for the stratum where the most signiﬁcant meta-analysis p was
observed. The colour reﬂects the correlation coefﬁcients (r2) of each genotyped SNP with the index SNP estimated using the CEU HapMap II panel.
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when all hits are considered and 2.1% if only GWS are
evaluated.
DISCUSSION
In this report we attempted to further clarify the genetic architec-
ture of the genetic background of hip OA by using the largest
sample-size for hip OA to-date of more than 78 000 genotyped
individuals under a GWAS framework. During the discovery
phase, we identiﬁed eight signals that qualiﬁed for further inde-
pendent replication. Of these, the signal at chromosome 20q13
near NCOA3 gene was found to be GWS and two other loci were
suggestively signiﬁcant at a p<5×10−6 level in the joint analysis
of the discovery and replication stages. Adjusted analyses of the
prioritised signals revealed that these markers were not associated
with body size. These genetic risk factors contribute to our
knowledge base in the ﬁeld of the susceptibility for hip OA by
conferring a medium OA risk.
The top signal identiﬁed in this meta-analysis was rs6094710, a
variant that is annotated on chromosome 20q13 near the NCOA3
gene, increasing the risk for hip OA for the carriers of the A allele
by almost 30%. Furthermore, we showed that the identiﬁed
NCOA3 gene was expressed in articular cartilage and its expres-
sion was signiﬁcantly reduced in OA affected cartilage, further
supporting a role of the NCOA3 gene signal in OA disease
process. Interestingly, rs6094710 is in complete linkage disequilib-
rium with rs6094752 (r2=1) which is a missense SNP leading to
an amino acid change at position 218 in the protein (Arg>Cys).
This amino acid change is predicted to have a benign and dam-
aging effect on the protein by PolyPhen-2,21 dependent on the
variant protein. The functional consequences of SNP rs6094752
are unknown, and further research is therefore needed to
unravel the biological mechanism of this amino acid change in
relation to OA.
The NCOA3 gene is a nuclear receptor coactivator that dir-
ectly binds nuclear receptors and stimulates the transcriptional
activities in a hormone-dependent fashion. In this signalling
process, NCOA3 recruits histone acetyltransferases and methyl-
transferases for chromatin remodelling and facilitating down-
stream gene transcription. NCOA3 is involved in the
coactivation of different nuclear receptors, such as for steroids,
retinoids, thyroid hormone, vitamin D3 and prostanoids. Many
of these hormones have been implicated in skeletal metabolism
and OA, which makes NCOA3 a compelling causal candidate
gene. Previously, NCOA3 knockout mice were generated
through homologous recombination in embryonic stem cells.22
These mice showed growth retardation and reduced adult
body size, but the molecular mechanism responsible for this
growth retardation remains largely unknown. In addition,
female mice exhibited abnormal development and function
of their reproductive system and oestrogen levels were signiﬁ-
cantly lower in the knockout mice compared with the wild
type,22 possibly indicating involvement of NCOA3 in steroid
regulation.
NCOA3 could be also implicated through regulation of the
target tissue responses to thyroid hormone (T3).23 Since intra-
cellular T3 is tightly regulated by deiodinase, iodothyronine,
type-2 and deiodinase, iodothyronine, type-3 encoded by the
DIO2 and DIO3 genes, respectively, that were previously recog-
nised as OA susceptibility genes,24 25 the current NCOA3 ﬁnd-
ings complement the previous outlined hypothesis that local T3
signalling may affect OA susceptibility.26
Another possible mechanism by which NCOA3 might be
involved in cartilage homoeostasis is through transcriptional
regulation in mechanotransduction. NCOA3 is upregulated by
the signal transducer and activator of transcription 6 (STAT6) in
naïve splenic B cells from BALB/c and serves as a positive regu-
lator of transcriptional activation by STAT6.27 STAT6 is known
to be the common signal transducer of interleukin (IL)-4 recep-
tor α chain and mediates IL-4- and IL-13-induced responses.28
Chondrocytes from normal and OA cartilage signal through a
type II IL-4R in in human articular chondrocyte mechanotrans-
duction. This signalling is via a STAT6-independent pathway.
Differences in IL-4 signalling are likely due to crosstalk between
integrin and cytokine signalling pathways.29 Therefore, NCOA3
may be related to cartilage function and molecular signalling
and transcriptional regulation in mechanotransduction.
The male-speciﬁc locus on 7p13, represented by rs3757837,
showed considerable heterogeneity between studies. The signal
was strongly supported by the RE model. Unlike the conserva-
tive traditional RE methods this new method has been shown to
achieve higher statistical power when heterogeneity exists,
allowing for new discoveries in the ﬁeld of genetic epidemi-
ology.14 rs3757837 is located in CAMK2B gene, which belongs
to the calcium/calmodulin-regulated kinase (CaMKII) subfamily.
Table 3 Summary of the genome-wide significant and suggestive SNPs for hip OA and their estimated heritability
Reference SNP Gene OR EAF λs Expected GV explained (%)
Genome wide significant findings (p<5×10−8)
This study rs6094710 NCOA3 1.28 0.04 1.0029 0.46
arcOGEN6 rs6976 GLT8D1 1.12 0.37 1.0031 0.60
arcOGEN6 rs11177 GNL3 1.12 0.38 1.0031 0.60
arcOGEN6 rs4836732 ASTN2 1.20 0.47 1.0083 1.66
arcOGEN6 rs9350591 FILIP1;SENP6 1.18 0.11 1.0030 0.54
arcOGEN6 rs10492367 KLHDC5;PTHLH 1.14 0.19 1.0029 0.53
3arcOGEN6 rs835487 CHST11 1.13 0.34 1.0034 0.67
TreatOA12 rs12982744 DOT1L 1.17 0.38 1.0060 1.16
Suggestive findings (5×10−6<p<5×10−8)
This study rs5009270 IFRD1 1.10 0.30 1.0019 0.38
This study rs3757837 CAMK2B 1.27 0.06 1.0040 0.64
arcOGEN6 rs12107036 TP63 1.21 0.52 1.0090 1.81
arcOGEN6 rs8044769 FTO 1.11 0.50 1.0027 0.54
arcOGEN6 rs10948172 SUPT3H;CDC5L 1.14 0.29 1.0037 0.71
EAF, effect allele frequency; GV, genetic variance; OA, osteoarthritis.
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There is evidence that CaMKII-signalling may be important in
onset and progression of OA.30 31 This pathway has been
described as central to the molecular events that regulate chon-
drocyte responses to mechanical stimulation and in particular,
to the upstream effect of IL-4. This would be linked to the
STAT6 pathway, which in turn is regulated by NCOA3. Thus
these two genetic signals, NCOA3 and CAMK2B, both point to
pathways related to cartilage mechanotransduction, suggesting
that genetic defects in this pathway may be central to the degen-
eration of cartilage that takes place in hip OA. OA is a disease
affecting articular cartilage and the underlying bone, resulting
from many biological and mechanical interacting factors which
change the extracellular matrix and cells and lead to increasing
levels of cartilage degeneration. Joint tissues are exquisitely sen-
sitive to their mechanical environment, and mechanical loading
may be the most important external factor regulating the devel-
opment and long-term maintenance of joint tissues.32 Finally,
rs5009270 resides near IFDRD1 which codes an interferon-
related developmental regulator and has been implicated in skel-
etal muscle regeneration.33 Reduction in muscle strength is
strongly associated with functional decline, and individuals with
lower quadriceps strength adjusted for body weight are more
likely to develop OA.34
Our study has certain limitations. In our discovery stage, two
out of the eight independent loci had no heterogeneity and in ﬁve
signals the heterogeneity was moderate or low. However, when we
included the replication data, large heterogeneity was introduced
for all SNPs. Conﬂicting results in the replication data, besides
chance, could be explained by inconsistent deﬁnitions of the OA
phenotypes but also from the different population structure that
can introduce heterogeneity. The TreatOA consortium has
addressed the need of standardisation of OA phenotypes35 and
this effort may have diminished the observed heterogeneity in the
discovery stage. Efforts including more data using common and
stringent QC criteria and standardisation methods should substan-
tially improve the power of GWAS to identify novel ﬁndings in the
near future. The main limitation of the expression study is that
there are few individuals included, in particular only two carriers
of the rs6094710 variant.
In conclusion, novel loci involved in hip OA were discovered
through a large-scale meta-analysis of GWAS. The exact under-
lying mechanism leading to a higher risk of OA remains to be elu-
cidated by functional experiments. It is evident from this work
and other recent studies that deciphering the architecture of the
genetics of OA requires major large-scale efforts, and in this
regard calls for international worldwide collaborations are not
fruitless. In the near future emphasis should be given to the
enhancement of the total sample size, the adoption of stringent
and standardised deﬁnitions of the phenotypes and the application
of imputation-based meta-analysis using the panel of the 1000
Genomes Project.36 In addition, linking results from genetic asso-
ciation studies to for example genome-wide RNA expression data
might further improve our understanding. Eventually, large-scale
studies with whole-genome sequencing will be needed to target
the heritability caused by less common variants.
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